PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider
Executive Summary
US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.
You may also be interested in...
Pandemic Taking Its Toll On The US FDA’s Non-Pandemic Work, Alkermes CEO Says
Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.
US FDA Drug Review Goals Should Be Faster In PDUFA VII, Industry Negotiators Propose
Sponsor representatives also want postmarketing discussions moved to earlier in the assessment cycle.
A More Perfect Meeting: Industry Seeks Additional PDUFA VII Metrics To Improve Communications
Will the US FDA agree to more structured communications amid its struggles with the existing meeting workload?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: